Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
24.42
+0.25 (1.03%)
Aug 5, 2026, 4:00 PM EDT - Market closed
Denali Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 387.63 | 205.33 | 174.96 | 127.11 | 218.04 | 293.48 |
Short-Term Investments | 600.06 | 662.55 | 657.37 | 907.41 | 1,118 | 571.93 |
Cash & Short-Term Investments | 987.68 | 867.88 | 832.33 | 1,035 | 1,336 | 865.41 |
Cash Growth | 20.76% | 4.27% | -19.54% | -22.58% | 54.40% | -41.12% |
Other Receivables | - | - | - | - | - | 1.23 |
Total Trade Receivables | - | - | - | - | - | 1.23 |
Other Current Assets | 35.07 | 32.78 | 32.11 | 29.63 | 36.1 | 30.6 |
Total Current Assets | 1,023 | 900.66 | 864.44 | 1,064 | 1,372 | 897.23 |
Net Property, Plant & Equipment | 117.27 | 119.94 | 125.63 | 71.64 | 74.52 | 69.61 |
Other Intangible Assets | 36 | - | - | - | - | - |
Long-Term Investments | 63.79 | 98.32 | 359.37 | - | - | 425.45 |
Other Long-Term Assets | 26.22 | 25.94 | 24.74 | 18.14 | 13.4 | 11.87 |
Total Assets | 1,266 | 1,145 | 1,374 | 1,154 | 1,460 | 1,404 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 40.38 | 3.33 | 11.14 | 9.48 | 2.79 | 4.78 |
Accrued Expenses | 69.78 | 95.02 | 91.07 | 68.5 | 66.69 | 53.17 |
Unearned Revenue | - | - | - | - | 290.05 | 320.3 |
Other Current Liabilities | - | - | - | - | 4.39 | - |
Total Current Liabilities | 110.16 | 98.35 | 102.21 | 77.98 | 363.92 | 378.25 |
Long-Term Leases | 30.19 | 32.74 | 42.29 | 44.98 | 53.03 | 58.55 |
Other Long-Term Liabilities | 199.58 | - | - | - | 0.86 | 5.07 |
Total Long-Term Liabilities | 229.77 | 32.74 | 42.29 | 44.98 | 53.89 | 63.63 |
Total Liabilities | 339.93 | 131.09 | 144.5 | 122.96 | 417.81 | 441.87 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 1.91 | 1.89 | 1.77 | 1.71 | 1.69 | 1.55 |
Additional Paid-in Capital | 3,105 | 3,063 | 2,765 | 2,145 | 2,019 | 1,608 |
Accumulated Other Comprehensive Income | -0.68 | 0.68 | 2.02 | 0.64 | -6.89 | -2.5 |
Retained Earnings | -2,180 | -2,052 | -1,539 | -1,116 | -970.99 | -645 |
Shareholders' Equity | 926.1 | 1,014 | 1,230 | 1,031 | 1,042 | 962.29 |
Total Liabilities & Equity | 1,266 | 1,145 | 1,374 | 1,154 | 1,460 | 1,404 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 30.19 | 32.74 | 42.29 | 44.98 | 53.03 | 58.55 |
Net Cash (Debt) | 957.5 | 835.14 | 790.04 | 989.53 | 1,283 | 806.85 |
Net Cash Growth | 24.46% | 5.71% | -20.16% | -22.88% | 59.04% | -42.59% |
Net Cash Per Share | 5.42 | 4.84 | 4.80 | 7.20 | 10.22 | 6.64 |
Book Value | 926.1 | 1,014 | 1,230 | 1,031 | 1,042 | 962.29 |
Book Value Per Share | 5.25 | 5.87 | 7.48 | 7.50 | 8.30 | 7.92 |
Tangible Book Value | 890.1 | 1,014 | 1,230 | 1,031 | 1,042 | 962.29 |
Tangible Book Value Per Share | 5.04 | 5.87 | 7.48 | 7.50 | 8.30 | 7.92 |